Gene-Panel Sequencing and the Prediction of Breast-Cancer Risk
Cet article passe en revue les données sur les performances des tests qui, à partir du séquençage d'un panel de gènes, visent à prédire un risque de cancer du sein
Advances in sequencing technology have made multigene testing, or “panel testing,” a practical option when looking for genetic variants that may be associated with a risk of breast cancer. In June 2013, the U.S. Supreme Court1 invalidated specific claims made by Myriad Genetics with respect to the patenting of the genomic DNA sequence of BRCA1 and BRCA2. Other companies immediately began to offer panel tests for breast cancer genes that included BRCA1 and BRCA2...
New England Journal of Medicine , article en libre accès, 2014